Targeted Therapy Resistance
Targeted Therapy Resistance - Related Videos
11:56
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
0 Views •
Cited by 4 •
2013
Acquired resistance to antibiotics is a major public healthcare problem and is presently ranked by the WHO as one of the greatest threats to human life. Here we describe the use of cantilever technology to quantify antibacterial resistance, critical to the discovery of novel and powerful agents against multidrug resistant bacteria.
08:59
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
0 Views •
Cited by 1 •
2017
This is a time- and cost-effective in vitro protocol investigating the mechanisms of acquired resistance to targeted therapeutic agents, which is a highly unmet medical need in cancer management.
02:57
Targeted Cancer Therapies
0 Views •
2021
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body. There are several types of targeted therapies against specific...
02:57
Targeted Cancer Therapies
0 Views •
2023
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body. There are several types of targeted therapies against specific...
08:03
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
0 Views •
Cited by 7 •
2016
Photodynamic therapy (PDT) is an alternative choice for lung cancer treatment. To increase the therapeutic effect of PDT, lung cancer-targeted nanoparticles combined with chemotherapy were developed. Both in vitro and in vivo anticancer efficacies of PDT with prepared nanoparticles were evaluated.
FAQs
Secondary mutations can change the molecular target’s drug-binding site, reducing the treatment’s ability to inhibit it. The cancer may therefore continue using the same target despite adequate treatment exposure. Detecting these alterations through tumor profiling can clarify why responsiveness has declined and help guide selection of a different treatment or a strategy designed to address the altered target.
Resistance may arise without altering the original drug-binding site. Cancer cells can activate bypass signaling pathways that deliver growth-related signals around the inhibited target, or change their cellular identity so that dependence on the original target decreases. Distinguishing these mechanisms matters because treatment decisions may need to address pathway activity or altered cell state rather than the initial target alone.
Altered drug transport or metabolism can reduce the amount of therapy reaching or remaining available to cancer cells. Even when the molecular target remains unchanged, insufficient exposure may weaken target inhibition and limit clinical benefit. Assessing this mechanism helps separate resistance caused by tumor biology from resistance associated with changes in how the treatment is handled in the body.
Tumor profiling can examine molecular features associated with loss of response, while a repeat biopsy provides newly collected tumor material for reassessment. A liquid biopsy offers another approach for evaluating tumor-related molecular changes. Used alongside clinical evaluation, these methods can reveal evolving resistance mechanisms and support treatment selection as the disease changes.
Biomarkers can help identify molecular changes linked to declining treatment responsiveness and may support monitoring over time. Their development connects resistance biology with treatment decisions and research design. When interpreted with tumor profiling, repeat biopsy, or liquid biopsy findings, biomarkers can help evaluate whether a therapeutic strategy continues to address the cancer’s current molecular features.
Identifying the mechanism of resistance can inform combination therapies that address more than one relevant process or sequential therapies selected after the initial treatment loses benefit. Resistance findings also support clinical trials testing approaches intended to extend durable responses. In medicine, this links molecular analysis with adaptive treatment planning rather than treating resistance as a single uniform event.